A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively

Sheila H. Ridner, Mary S. Dietrich, Kandace Spotanski, Jennifer K. Doersam, Michael S. Cowher, Bret Taback, Sarah McLaughlin, Nicolas Ajkay, John Boyages, Louise Koelmeyer, Sarah DeSnyder, Chirag Shah, Frank Vicini

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Data regarding pretreatment, bioimpedance spectroscopy (BIS) L-Dex® values for patients newly diagnosed with breast cancer, and longitudinal data 12 months postoperatively are lacking. This study describes L-Dex values at the time of breast cancer diagnosis and maximum L-Dex change within 12 months of surgery.

Methods and results: Patients were enrolled in a parent, clinical trial that compares the effectiveness of BIS for early detection of breast cancer-related lymphedema to tape measurement. A total of 280 women with a pretreatment and at least one postoperative L-Dex measurement (within 12 months of surgery) were included. Pretreatment L-Dex readings were compared with population norms and maximum L-Dex changes within 12 months were examined. An L-Dex U400 device was used to obtain BIS measurements. The documented normative mean value using this device is 0.00, which is at the 49th percentile for this sample. Approximately 6% of patients had a pretreatment L-Dex value of ≥7.0; 1.8% had an L-Dex value ≥10.0. For 12 months, 17.1% (n = 48) of patients had a maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units, suggestive of clinical lymphedema.

Conclusions: At the time of breast cancer diagnosis, L-Dex values are similar to normative values. Identified maximum changes in L-Dex values 12 months postoperatively suggest that frequent L-Dex measurements during that time frame are of potential clinical benefit. Our findings are consistent with research supporting an L-Dex value of ≥7 as indicative of clinical lymphedema with subclinical lymphedema logically occurring at somewhat lower likely, near ≥6.5

LanguageEnglish
Pages435-441
Number of pages7
JournalLymphatic Research and Biology
Volume16
Issue number5
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Lymphedema
Prospective Studies
Breast Neoplasms
Spectrum Analysis
Equipment and Supplies
Early Detection of Cancer
Reading
Clinical Trials
Research
Population

Keywords

  • bioimpedance
  • breast cancer
  • detection
  • lymphedema

Cite this

Ridner, S. H., Dietrich, M. S., Spotanski, K., Doersam, J. K., Cowher, M. S., Taback, B., ... Vicini, F. (2018). A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively. Lymphatic Research and Biology, 16(5), 435-441. https://doi.org/10.1089/lrb.2017.0070
Ridner, Sheila H. ; Dietrich, Mary S. ; Spotanski, Kandace ; Doersam, Jennifer K. ; Cowher, Michael S. ; Taback, Bret ; McLaughlin, Sarah ; Ajkay, Nicolas ; Boyages, John ; Koelmeyer, Louise ; DeSnyder, Sarah ; Shah, Chirag ; Vicini, Frank. / A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively. In: Lymphatic Research and Biology. 2018 ; Vol. 16, No. 5. pp. 435-441.
@article{76f65b5d2a7c461c90f404c76cce8d95,
title = "A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively",
abstract = "Background: Data regarding pretreatment, bioimpedance spectroscopy (BIS) L-Dex{\circledR} values for patients newly diagnosed with breast cancer, and longitudinal data 12 months postoperatively are lacking. This study describes L-Dex values at the time of breast cancer diagnosis and maximum L-Dex change within 12 months of surgery.Methods and results: Patients were enrolled in a parent, clinical trial that compares the effectiveness of BIS for early detection of breast cancer-related lymphedema to tape measurement. A total of 280 women with a pretreatment and at least one postoperative L-Dex measurement (within 12 months of surgery) were included. Pretreatment L-Dex readings were compared with population norms and maximum L-Dex changes within 12 months were examined. An L-Dex U400 device was used to obtain BIS measurements. The documented normative mean value using this device is 0.00, which is at the 49th percentile for this sample. Approximately 6{\%} of patients had a pretreatment L-Dex value of ≥7.0; 1.8{\%} had an L-Dex value ≥10.0. For 12 months, 17.1{\%} (n = 48) of patients had a maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units, suggestive of clinical lymphedema.Conclusions: At the time of breast cancer diagnosis, L-Dex values are similar to normative values. Identified maximum changes in L-Dex values 12 months postoperatively suggest that frequent L-Dex measurements during that time frame are of potential clinical benefit. Our findings are consistent with research supporting an L-Dex value of ≥7 as indicative of clinical lymphedema with subclinical lymphedema logically occurring at somewhat lower likely, near ≥6.5",
keywords = "bioimpedance, breast cancer, detection, lymphedema",
author = "Ridner, {Sheila H.} and Dietrich, {Mary S.} and Kandace Spotanski and Doersam, {Jennifer K.} and Cowher, {Michael S.} and Bret Taback and Sarah McLaughlin and Nicolas Ajkay and John Boyages and Louise Koelmeyer and Sarah DeSnyder and Chirag Shah and Frank Vicini",
year = "2018",
month = "10",
day = "1",
doi = "10.1089/lrb.2017.0070",
language = "English",
volume = "16",
pages = "435--441",
journal = "Lymphatic Research and Biology",
issn = "1539-6851",
publisher = "Mary Ann Liebert",
number = "5",

}

Ridner, SH, Dietrich, MS, Spotanski, K, Doersam, JK, Cowher, MS, Taback, B, McLaughlin, S, Ajkay, N, Boyages, J, Koelmeyer, L, DeSnyder, S, Shah, C & Vicini, F 2018, 'A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively' Lymphatic Research and Biology, vol. 16, no. 5, pp. 435-441. https://doi.org/10.1089/lrb.2017.0070

A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively. / Ridner, Sheila H.; Dietrich, Mary S.; Spotanski, Kandace; Doersam, Jennifer K.; Cowher, Michael S.; Taback, Bret; McLaughlin, Sarah; Ajkay, Nicolas; Boyages, John; Koelmeyer, Louise; DeSnyder, Sarah; Shah, Chirag; Vicini, Frank.

In: Lymphatic Research and Biology, Vol. 16, No. 5, 01.10.2018, p. 435-441.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A prospective study of L-Dex values in breast cancer patients pretreatment and through 12 months postoperatively

AU - Ridner,Sheila H.

AU - Dietrich,Mary S.

AU - Spotanski,Kandace

AU - Doersam,Jennifer K.

AU - Cowher,Michael S.

AU - Taback,Bret

AU - McLaughlin,Sarah

AU - Ajkay,Nicolas

AU - Boyages,John

AU - Koelmeyer,Louise

AU - DeSnyder,Sarah

AU - Shah,Chirag

AU - Vicini,Frank

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Data regarding pretreatment, bioimpedance spectroscopy (BIS) L-Dex® values for patients newly diagnosed with breast cancer, and longitudinal data 12 months postoperatively are lacking. This study describes L-Dex values at the time of breast cancer diagnosis and maximum L-Dex change within 12 months of surgery.Methods and results: Patients were enrolled in a parent, clinical trial that compares the effectiveness of BIS for early detection of breast cancer-related lymphedema to tape measurement. A total of 280 women with a pretreatment and at least one postoperative L-Dex measurement (within 12 months of surgery) were included. Pretreatment L-Dex readings were compared with population norms and maximum L-Dex changes within 12 months were examined. An L-Dex U400 device was used to obtain BIS measurements. The documented normative mean value using this device is 0.00, which is at the 49th percentile for this sample. Approximately 6% of patients had a pretreatment L-Dex value of ≥7.0; 1.8% had an L-Dex value ≥10.0. For 12 months, 17.1% (n = 48) of patients had a maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units, suggestive of clinical lymphedema.Conclusions: At the time of breast cancer diagnosis, L-Dex values are similar to normative values. Identified maximum changes in L-Dex values 12 months postoperatively suggest that frequent L-Dex measurements during that time frame are of potential clinical benefit. Our findings are consistent with research supporting an L-Dex value of ≥7 as indicative of clinical lymphedema with subclinical lymphedema logically occurring at somewhat lower likely, near ≥6.5

AB - Background: Data regarding pretreatment, bioimpedance spectroscopy (BIS) L-Dex® values for patients newly diagnosed with breast cancer, and longitudinal data 12 months postoperatively are lacking. This study describes L-Dex values at the time of breast cancer diagnosis and maximum L-Dex change within 12 months of surgery.Methods and results: Patients were enrolled in a parent, clinical trial that compares the effectiveness of BIS for early detection of breast cancer-related lymphedema to tape measurement. A total of 280 women with a pretreatment and at least one postoperative L-Dex measurement (within 12 months of surgery) were included. Pretreatment L-Dex readings were compared with population norms and maximum L-Dex changes within 12 months were examined. An L-Dex U400 device was used to obtain BIS measurements. The documented normative mean value using this device is 0.00, which is at the 49th percentile for this sample. Approximately 6% of patients had a pretreatment L-Dex value of ≥7.0; 1.8% had an L-Dex value ≥10.0. For 12 months, 17.1% (n = 48) of patients had a maximum change in L-Dex value from pretreatment of ≥7.0 L-Dex units, suggestive of clinical lymphedema.Conclusions: At the time of breast cancer diagnosis, L-Dex values are similar to normative values. Identified maximum changes in L-Dex values 12 months postoperatively suggest that frequent L-Dex measurements during that time frame are of potential clinical benefit. Our findings are consistent with research supporting an L-Dex value of ≥7 as indicative of clinical lymphedema with subclinical lymphedema logically occurring at somewhat lower likely, near ≥6.5

KW - bioimpedance

KW - breast cancer

KW - detection

KW - lymphedema

UR - http://www.scopus.com/inward/record.url?scp=85055073641&partnerID=8YFLogxK

U2 - 10.1089/lrb.2017.0070

DO - 10.1089/lrb.2017.0070

M3 - Article

VL - 16

SP - 435

EP - 441

JO - Lymphatic Research and Biology

T2 - Lymphatic Research and Biology

JF - Lymphatic Research and Biology

SN - 1539-6851

IS - 5

ER -